Sofinnova Partners Raises €1.2 Billion to Drive Life Sciences Innovation
Sofinnova Partners, a leading European venture capital firm based in Paris, London, and Milan, has successfully raised €1.2 billion across its various investment strategies over the past year. More than €1 billion of this funding was secured in the last quarter alone. This remarkable achievement brings it’s total assets under management (AUM) to over €4 billion, reinforcing its position as a premier investor in transformative innovations within healthcare and sustainability.
Further details about individual funds will be disclosed upon their final closings.
Sofinnova’s Expanding Investment Platform
Sofinnova’s latest fundraising efforts span a wide array of investment strategies, from early-stage incubation to later-stage growth. The firm’s focus includes biotech, medtech, industrial biotech, and digital medicine. These new funds are designed to support the next generation of life sciences companies, particularly those with the potential to address pressing global challenges in health and sustainability.
Antoine Papiernik, Chairman and Managing Partner of it’s Partners, highlighted the firm’s broad investment mandate: “All seven of it’s investment strategies—from incubation to later-stage growth, spanning biotech, medtech, industrial biotech, and digital medicine—have capital to back the next generation of life sciences companies.” Papiernik added that the firm anticipates backing 50 to 60 new companies with these funds, empowering entrepreneurs to tackle some of the world’s most urgent issues.
Investor Confidence Drives Strong Commitments
Sofinnova’s fundraising success reflects strong support from a diverse group of institutional investors, sovereign wealth funds, corporate partners, and family offices. This significant backing underscores the confidence investors have in it’s ability to identify, fund, and nurture high-potential opportunities across the life sciences sector.
The firm’s impressive track record of identifying and scaling breakthrough innovations in healthcare and sustainability further bolsters its reputation as a leading investor in these critical fields.
A Globally Connected Team of Experts
Over the past decade, Sofinnova has built one of the most experienced and globally connected teams in life sciences investing. Today, the firm boasts over 80 professionals, including 25 investment partners who bring deep sector expertise to their work. With a team spanning 24 nationalities and offices in key innovation hubs worldwide, it is well-positioned to tap into global opportunities and continue its mission of supporting groundbreaking life sciences companies.
The diverse and highly skilled team is instrumental in providing the deep sector knowledge and operational support that portfolio companies need to succeed, whether in biotech, medtech, industrial biotech, or digital medicine.
Embracing Technology with Sofinnova.ai
In a move to further strengthen its investment capabilities,it has embraced cutting-edge technology. The firm recently launched Sofinnova.ai, an AI-powered platform developed over the last five years. This advanced platform is designed to revolutionize how it sources, analyzes, and supports breakthrough science and entrepreneurs.
By utilizing data analytics and machine learning, it is enhancing its decision-making process and improving its ability to identify disruptive innovations at an early stage. The AI platform’s capabilities allow the firm to better predict emerging trends and assess the potential of new technologies, enabling it to maintain its competitive edge in the life sciences investment space.
Supporting the Next Wave of Life Sciences Innovation
With its substantial new funding and cutting-edge technological tools, it’s Partners is poised to accelerate the growth of the next wave of life sciences innovation. The firm’s strategic approach, backed by strong investor confidence and a globally connected team, positions to continue playing a pivotal role in shaping the future of healthcare and sustainability.
By empowering entrepreneurs and supporting disruptive companies at every stage of their development, it is driving progress in addressing the world’s most urgent health and environmental challenges. Through its combined expertise in life sciences, deep network, and innovative technology, Sofinnova is uniquely positioned to lead the charge in transforming the healthcare and sustainability sectors for years to come.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London, and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical, and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is deeply established in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit: sofinnovapartners.com.
